(Total Views: 384)
Posted On: 10/03/2019 11:19:27 AM
Post# of 72445
No, just objective concerns based upon past experiences. Small trial sizes have bit us twice. Had there been an extra 10-15 patients in the B-OM and Prurisol 2a trials we would likely be a very different company right now.
With B-OM our results would have been more conclusive and we probably would have received BTD.
With Prurisol 2a we probably would have seen that it was not worth pursuing an expensive and company-damaging phase 2b.
With B-OM our results would have been more conclusive and we probably would have received BTD.
With Prurisol 2a we probably would have seen that it was not worth pursuing an expensive and company-damaging phase 2b.
(2)
(0)
